Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Granulocyte-macrophage colony-stimulating factor-containing medium for blastocyst recovery culture: study protocol for a randomized controlled trial (GSET-study).

Trials·2026
Same author

Differentiation of mesenchymal stem/stromal cells into CD45<sup>+</sup> macrophage-like cells: expanding insights into MSC plasticity.

iScience·2026
Same author

Tracking adipose-derived mesenchymal stromal cells in the eye: Integrating IVIS imaging and Alu PCR for enhanced detection of human cells.

Regenerative therapy·2025
Same author

Associations between retinal thickness and background factors in eyes without retinal diseases.

Scientific reports·2025
Same author

Human corneal organoid has a limbal function that supplies epithelium to the cornea with limbal deficiency.

Regenerative therapy·2025
Same author

Author Correction: Exploratory study on the efficacy of topical pan-JAK inhibitor in ocular and skin GVHD in a sclerodermatous GVHD mouse model.

Scientific reports·2025

Related Experiment Video

Updated: Jan 6, 2026

Efficient and Scalable Directed Differentiation of Clinically Compatible Corneal Limbal Epithelial Stem Cells from Human Pluripotent Stem Cells
10:07

Efficient and Scalable Directed Differentiation of Clinically Compatible Corneal Limbal Epithelial Stem Cells from Human Pluripotent Stem Cells

Published on: October 24, 2018

8.1K

Review: corneal endothelial cell derivation methods from ES/iPS cells.

Shin Hatou1, Shigeto Shimmura1

  • 1Department of Ophthalmology, Keio University School of Medicine, 35 Shinanomchi, Shinjuku-ku, Tokyo, Japan.

Inflammation and Regeneration
|October 9, 2019
PubMed
Summary

Regenerative therapy using stem cells offers a promising solution for corneal blindness, addressing the significant gap in corneal transplantation needs. Research is advancing methods to derive corneal endothelial cells from stem cells for future therapies.

Keywords:
Bone morphogenetic proteinEmbryonic stem cellsEpithelial-mesenchymal transitionInduced pluripotent stem cellsNeural crest cellsTransforming growth factor betaWnt

More Related Videos

Growth of Human and Sheep Corneal Endothelial Cell Layers on Biomaterial Membranes
05:20

Growth of Human and Sheep Corneal Endothelial Cell Layers on Biomaterial Membranes

Published on: February 6, 2020

8.2K
Efficient Derivation of Retinal Pigment Epithelium Cells from Stem Cells
07:07

Efficient Derivation of Retinal Pigment Epithelium Cells from Stem Cells

Published on: March 8, 2015

9.6K

Related Experiment Videos

Last Updated: Jan 6, 2026

Efficient and Scalable Directed Differentiation of Clinically Compatible Corneal Limbal Epithelial Stem Cells from Human Pluripotent Stem Cells
10:07

Efficient and Scalable Directed Differentiation of Clinically Compatible Corneal Limbal Epithelial Stem Cells from Human Pluripotent Stem Cells

Published on: October 24, 2018

8.1K
Growth of Human and Sheep Corneal Endothelial Cell Layers on Biomaterial Membranes
05:20

Growth of Human and Sheep Corneal Endothelial Cell Layers on Biomaterial Membranes

Published on: February 6, 2020

8.2K
Efficient Derivation of Retinal Pigment Epithelium Cells from Stem Cells
07:07

Efficient Derivation of Retinal Pigment Epithelium Cells from Stem Cells

Published on: March 8, 2015

9.6K

Area of Science:

  • Ophthalmology and Regenerative Medicine
  • Stem Cell Biology and Tissue Engineering

Background:

  • A critical global shortage exists for corneal transplantation, with 12.7 million patients awaiting procedures against only 185,000 annual transplants.
  • Corneal endothelial dysfunction, including bullous keratopathy from Fuchs' dystrophy or surgical complications, accounts for half of all corneal transplant indications.
  • Developing regenerative therapies for corneal endothelium independent of donor corneas is crucial to bridge the supply-demand gap and combat corneal blindness.

Purpose of the Study:

  • To review and analyze methods for deriving corneal endothelial cells (CECs) from pluripotent stem cells (ESCs/iPSCs).
  • To explore the developmental mechanisms underlying CEC differentiation, including key signaling pathways.
  • To assess the progress and challenges in translating these stem cell-derived CECs towards clinical applications for bullous keratopathy.

Main Methods:

  • Review of four representative methods for deriving CECs from embryonic stem (ES) or induced pluripotent stem (iPS) cells.
  • Analysis of evolving culture media components, transitioning from undefined sources (e.g., fetal bovine serum) to chemically defined media with recombinant proteins and small molecules.
  • Examination of research elucidating the roles of TGF-beta, BMP, and Wnt signaling in epithelial-mesenchymal and mesenchymal-endothelial transitions during CEC development.

Main Results:

  • Significant advancements have been made in refining CEC derivation protocols, moving towards chemically defined and more efficient methods.
  • Key developmental pathways (TGF-beta, BMP, Wnt) have been identified as critical regulators of CEC differentiation from stem cells.
  • Current protocols show promise for clinical translation, though further optimization is needed.

Conclusions:

  • Stem cells (ESCs/iPSCs) represent an ideal cell source for regenerative therapy to treat corneal endothelial dysfunction, potentially solving the transplant shortage.
  • Progress in understanding CEC developmental biology has enabled the development of improved, chemically defined derivation protocols.
  • Future research must focus on rigorous proof of efficacy and safety in adequate animal models to facilitate clinical application of stem cell-derived CECs.